REGISTERED NUMBER: |
Unaudited Financial Statements |
For The Year Ended 31 August 2024 |
for |
JAJ PHARMA LIMITED |
REGISTERED NUMBER: |
Unaudited Financial Statements |
For The Year Ended 31 August 2024 |
for |
JAJ PHARMA LIMITED |
JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693) |
Contents of the Financial Statements |
For The Year Ended 31 August 2024 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 4 |
JAJ PHARMA LIMITED |
Company Information |
For The Year Ended 31 August 2024 |
DIRECTORS: |
SECRETARY: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
Accountants & Tax Advisers |
79 College Road |
Harrow |
Middlesex |
HA1 1BD |
JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693) |
Balance Sheet |
31 August 2024 |
31.8.24 | 31.8.23 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Tangible assets | 4 |
Investments | 5 |
CURRENT ASSETS |
Debtors | 6 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 7 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
CREDITORS |
Amounts falling due after more than one year | 8 |
NET ASSETS |
CAPITAL AND RESERVES |
Called up share capital | 11 |
Retained earnings |
SHAREHOLDERS' FUNDS |
The directors acknowledge their responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693) |
Balance Sheet - continued |
31 August 2024 |
The financial statements were approved by the Board of Directors and authorised for issue on |
JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693) |
Notes to the Financial Statements |
For The Year Ended 31 August 2024 |
1. | STATUTORY INFORMATION |
JAJ Pharma Limited is a |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Turnover |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
Tangible fixed assets |
Plant and machinery etc | - |
Investments in associates |
Investments in associate undertakings are recognised at cost. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the year was |
JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693) |
Notes to the Financial Statements - continued |
For The Year Ended 31 August 2024 |
4. | TANGIBLE FIXED ASSETS |
Plant and |
machinery |
etc |
£ |
COST |
Additions |
At 31 August 2024 |
DEPRECIATION |
Charge for year |
At 31 August 2024 |
NET BOOK VALUE |
At 31 August 2024 |
5. | FIXED ASSET INVESTMENTS |
Interest |
in |
associate |
£ |
COST |
At 1 September 2023 | 54 |
Disposals | ( |
) |
At 31 August 2024 |
NET BOOK VALUE |
At 31 August 2024 |
At 31 August 2023 |
On 6th November 2023,the following disposals took place: |
18 Ordinary shares in Liqmeds Worldwide Limited were sold for an upfront consideration of £5,242,317.82 and a further ascertainable deferred consideration of £15,534,400.00 receivable on an earn out basis over 3 years from date of completion. |
36 Ordinary shares in Medsolutions (Europe) Limited were sold for an upfront consideration of £204,098.89 and a further ascertainable deferred consideration of £604,800.00 receivable on an earn out basis over 3 years from date of completion. |
JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693) |
Notes to the Financial Statements - continued |
For The Year Ended 31 August 2024 |
6. | DEBTORS |
31.8.24 | 31.8.23 |
£ | £ |
Amounts falling due within one year: |
Trade debtors |
Other debtors |
Amounts falling due after more than one year: |
Other debtors |
Aggregate amounts |
Other debtors balance due within 1 year includes £230,273 loaned to Sapphire Investments Group Ltd. |
Other Debtors balance of amounts due more than 1year refers to an amount of £16,139,200 of ascertainable deferred consideration to be received on an earn out basis over 3 years.. |
7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
31.8.24 | 31.8.23 |
£ | £ |
Taxation and social security |
Other creditors |
8. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |
31.8.24 | 31.8.23 |
£ | £ |
Bank loans (see note 9) |
Hire purchase contracts (see note 10) |
9. | LOANS |
An analysis of the maturity of loans is given below: |
31.8.24 | 31.8.23 |
£ | £ |
Amounts falling due between two and five years: |
Bank loans - 2-5 years |
JAJ PHARMA LIMITED (REGISTERED NUMBER: 10000693) |
Notes to the Financial Statements - continued |
For The Year Ended 31 August 2024 |
9. | LOANS - continued |
The company received a government backed bounce back loan for £50,000 on 2nd October 2020 and repaid the loan in full during the year. |
10. | LEASING AGREEMENTS |
Minimum lease payments under hire purchase fall due as follows: |
31.8.24 | 31.8.23 |
£ | £ |
Net obligations repayable: |
Between one and five years |
On 19th April 2024 the company entered into a 3 year Hire Purchase agreement, with the option to purchase the asset for £47,675.00 at the end of term. |
11. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Number: | Class: | Nominal | 31.8.24 | 31.8.23 |
value: | £ | £ |
Ordinary | 1 | 100 | 100 |
The shareholdings in the company are as follows; |
Mansi Jaykumar Jani 80 Ordinary Shares of £1 each |
Sanket Pankajkumar Soni 10 Ordinary Shares of £1 each |
Krupa Dave 10 Ordinary Shares of £1 each |